Men with coronary artery disease who used phosphodiesterase-5 (PDE-5) inhibitors for erectile dysfunction had fewer adverse cardiovascular events than those taking the prostaglandin drug alprostadil ...

Men with stable CAD who are being treated for erectile dysfunction (ED) have a lower risk of dying if their medication is a phosphodiesterase 5 (PDE5) inhibitor rather than alprostadil, observational ...

Did you know that problems with getting an erection when aroused can be your body's way of telling you to take a look at your ...

Use of a phosphodiesterase type-5 (PDE5) inhibitor was associated with a lower risk for death and cardiovascular events than alprostadil for the treatment of erectile dysfunction in men with stable ...

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago. A study from ...

Men who filled prescriptions for erectile dysfunction drugs in the years following a heart attack had a substantially lower risk of dying or being hospitalized for heart failure than men who did not ...

Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...

SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for ...

Dear Dr. Roach: Recently a reader asked about treatment and causes for erectile dysfunction. You did mention Viagra for the problem; however, you did not say that about 50 percent of men will have ...

Taxpayers paid more than $3.1 million in 2007 and 2008 for sexual or erectile dysfunction drugs such as Viagra that should not have been reimbursed under federal rules for Part D, according to a ...